How Did This Company With Just 1% Profits Outperform Google Stock?

The McKesson Growth Enigma: Unraveling the Stock Performance of a Healthcare Giant

When it comes to stock market success, many investors immediately think of tech giants like Google (now part of Alphabet, ticker GOOG). However, one company that has defied expectations and outperformed even these high-flyers is McKesson (ticker MCK), a stalwart in the healthcare industry. While Google’s stock has grown by 92% over the past five years, McKesson’s stock has surged by an astonishing 284%, quadrupling in value. This growth is particularly remarkable given that McKesson operates in a sector known for thin profit margins. Its net income margin is a modest 1.1%, yet the company has managed to deliver returns that even the most profitable tech companies would envy. This analysis delves into the key drivers behind McKesson’s remarkable stock performance and what it means for investors.

The Factors Behind McKesson’s Stellar Stock Performance

The extraordinary growth of McKesson’s stock can be attributed to three primary factors. First, there has been a significant increase in its trailing adjusted price-to-earnings (P/E) ratio, which has nearly doubled from 11x in 2020 to 22x today. This surge reflects investor confidence in the company’s strategic transformation and its ability to generate more sustainable profits. Second, McKesson has achieved a 49% increase in revenues, rising from $231 billion in 2020 to $345 billion in 2024. This growth has been fueled by its expanding role in healthcare distribution and specialized pharmaceuticals. Lastly, the company has reduced its total shares outstanding by 28%, from approximately 175 million to 130 million, partly through a $13 billion share buyback program. While its net income margin has dipped slightly from 1.2% to 1.1%, the overall impact on profitability has been mitigated by higher sales and operational efficiency. These factors combined have made McKesson a standout performer in the stock market, even when compared to high-growth tech companies like Google, which has seen a 30% decline in its P/E ratio alongside its 174% rise in earnings per share.

McKesson’s Earnings Transformation: Strategic Growth and Operational Efficiency

At the heart of McKesson’s success is its earnings transformation, driven by significant increases in both sales and operating income. The company’s revenue growth of nearly 50% over the past five years is a testament to its strategic initiatives. One of the key contributors to this growth was McKesson’s pivotal role in the COVID-19 response efforts. As the centralized distributor for vaccines, tests, and medical supplies for the U.S. government, the company saw a significant boost in demand for its services during the pandemic. This newfound visibility and importance in the healthcare ecosystem have had a lasting impact on its business. Additionally, McKesson has strategically expanded its pharmaceutical distribution business, particularly in the high-margin specialty pharmaceuticals sector. This includes oncology and other complex therapeutic areas, where demand has been steadily increasing. The company has also made shrewd acquisitions, such as Rx Savings Solutions, OncoHealth, and a controlling stake in Florida Cancer Specialists & Research Institutes, which have further strengthened its position in the oncology and biopharma services market.

McKesson’s Valuation Surge and Market Resilience

McKesson’s stock price has been further bolstered by its valuation surge, with its trailing P/E ratio doubling from 11x to 22x since 2020. This increase reflects investor confidence in the company’s strategic pivot toward higher-margin sectors and its ability to deliver sustainable profits. Unlike many companies that saw their valuations suffer during recent market turbulence, McKesson has demonstrated remarkable resilience. In 2022, while Google’s stock fell by over 30%, McKesson recorded gains of more than 50%. This performance underscores the company’s role as a vital component of healthcare infrastructure, making it an attractive option for investors seeking defensive investments during economic uncertainty. McKesson’s ability to generate steady cash flows has also been a key factor in its market resilience. Its stock has consistently outperformed broader market indices, with a peak-to-trough decline of only 11.0% in 2022 compared to the S&P 500’s 25.4% drop. This stability has further cemented its reputation as a reliable investment during stressful market conditions.

The Path Forward for Investors: Balancing Growth and Stability

For investors seeking upside potential with less volatility than individual stocks, the Trefis High-Quality Portfolio offers a compelling alternative. This portfolio, which has outperformed the S&P 500 and delivered returns exceeding 91% since its inception, is designed to provide steadier returns with lower risk. By focusing on high-quality stocks with strong fundamentals and proven track records, the portfolio offers a smoother ride for investors while still capturing significant upside. Given McKesson’s success and the broader market’s volatility, this approach could be particularly appealing to those looking to balance growth and stability in their investment strategy.

Invest with Trefis: Market-Beating Portfolios for Rules-Based Wealth

For those who want to capitalize on the market’s potential without the volatility of individual stocks, Trefis offers a range of market-beating portfolios designed on the principles of rules-based wealth creation. With a focus on high-quality stocks and a track record of outperforming the S&P 500, these portfolios provide a proven path to financial success. Whether you’re a seasoned investor or just starting your journey, Trefis’ approach can help you achieve your investment goals with confidence and clarity.